Vycor Medical reports 2024 revenue up 9% to $1.59M; engages Maxim Group for strategic growth

VYCOR MEDICAL INC

2025-Q1 EPS reported -$0.01 revenue$436,378

Revenue $1,589,324 (+9% YoY); Vycor Medical division revenue up 10% to $1,515,744.
Gross margin 89%; non-GAAP cash operating expenses $1.34M (+$136K); non-GAAP operating profit $81,548 down from $111,084.
US hospital sales up 17% with 11 new hospitals; eight new peer-reviewed studies published on ViewSite Brain Access System.
Engaged Maxim Group LLC to assist with corporate strategy including M&A, partnerships, and potential uplisting to a US exchange.
Products manufactured in US; tariffs not expected to directly impact costs but may affect exports and raw material supply.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.